...
首页> 外文期刊>Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia >The therapeutic efficacy of fractionated radiotherapy and gamma-knife radiosurgery for craniopharyngiomas.
【24h】

The therapeutic efficacy of fractionated radiotherapy and gamma-knife radiosurgery for craniopharyngiomas.

机译:分次放疗和伽玛刀放射治疗颅咽管瘤的疗效。

获取原文
获取原文并翻译 | 示例
           

摘要

There is no consensus regarding the optimal timing of radiation treatment (RT) for residual or recurrent craniopharyngioma or the preferred treatment modality between fractionated radiotherapy (FRT) and gamma-knife radiosurgery (GKRS) in terms of morbidity and efficacy. This study aims to clarify the optimal timing of RT for residual or recurrent tumors by analyzing the outcomes of RT as a salvage or adjunctive treatment, and to compare the therapeutic efficacy of FRT and GKRS. Between April 1995 and November 2009, 50 of 129 patients received RT for recurrent or residual tumors. The patients were analyzed for medical data, endocrine outcome, long-term morbidity and mortality rates, recurrence rates, and responses to adjuvant RT and GKRS. Mean progression-free survival was 92.5 months (95% confidence interval, 70.9-114.1 months). Univariate analysis revealed that pre-irradiation tumor volume was closely related to better prognosis (p=0.01). We found that there was no significant difference in recurrence between patients treated with adjuvant compared to salvage RT (p>0.05). Although we found no difference in the efficacy of FRT and GKRS, five patients were newly diagnosed with hypopituitarism following RT. We concluded that RT has a very high rate of tumor control after both adjuvant or salvage RT. This study highlights the relative safety and efficacy of FRT and GKRS.
机译:对于残存或复发性颅咽管瘤的最佳放疗时间(RT)或分次放疗(FRT)和伽玛刀放射手术(GKRS)之间在发病率和疗效方面的首选治疗方式尚无共识。本研究旨在通过分析作为抢救或辅助治疗的RT的结果,为残留或复发性肿瘤明确RT的最佳时机,并比较FRT和GKRS的治疗效果。在1995年4月至2009年11月之间,有129例患者中有50例因复发或残留肿瘤接受了放疗。分析了患者的医学数据,内分泌结果,长期发病率和死亡率,复发率以及对辅助RT和GKRS的反应。平均无进展生存期为92.5个月(95%置信区间为70.9-114.1个月)。单因素分析表明,放疗前的肿瘤体积与预后较好相关(p = 0.01)。我们发现,与挽救性放疗相比,接受佐剂治疗的患者之间的复发率无显着差异(p> 0.05)。尽管我们发现FRT和GKRS的疗效无差异,但有5例患者在RT后被新诊断为垂体功能低下。我们得出结论,在辅助或挽救性放疗后,放疗均具有很高的肿瘤控制率。这项研究强调了FRT和GKRS的相对安全性和有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号